2seventy bio (TSVT) has released an update.
The Company and BMS have announced an upcoming FDA advisory committee meeting to discuss the supplemental Biologics License Application for Abecma, a treatment for multiple myeloma, based on promising Phase 3 study results. This meeting, scheduled for March 15, 2024, will focus on the drug’s impact on overall survival in patients who have previously been treated with multiple therapies.
For further insights into TSVT stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
